|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general, and administrative expenses | |||||
| Research and development expenses | |||||
| Intellectual property agreement and certain litigation expenses (Note 3) | |||||
| Change in fair value of contingent consideration liabilities (Note 13) | |||||
| Special charge and separation costs (Note 4) | |||||
| Restructuring charges, separation costs, and other (Note 4) | |||||
| Intangible assets impairment charges | |||||
| Other operating income | |||||
| Operating income | |||||
| Interest expense | |||||
| Interest income | |||||
| Loss on impairment | |||||
| Other non-operating income, net (Note 18) | |||||
| Income from continuing operations before provision for income taxes | |||||
| Provision for income taxes (Note 19) | |||||
| Net income from continuing operations | |||||
| Income from discontinued operations, net of tax | |||||
| Net income | |||||
| Less: Net loss attributable to noncontrolling interest | |||||
| Net income attributable to Edwards Lifesciences Corporation. | |||||
| Share information (Note 2): | |||||
| Earnings per share attributable to Edwards Lifesciences Corporation: | |||||
| Basic | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Basic earnings per share (in dollars per share) | |||||
| Diluted: | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Diluted earnings per share (in dollars per share) | |||||
| Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) |
Loading...